5-Aminosalicylic acid and chemoprevention: Does it work?

Digestive Diseases

Volumn 31, Issue 2, 2013, Pages 248-253

  Lopez, Anthony ^a   Peyrin Biroulet, Laurent ^a,b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

5 Aminosalicylic acid; Chemoprevention; Colorectal cancer; Inflammatory bowel disease

Indexed keywords

AMINOSALICYLIC ACID; MESALAZINE; REACTIVE OXYGEN METABOLITE; SALAZOSULFAPYRIDINE; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; WNT PROTEIN; BETA CATENIN; CYCLOOXYGENASE 2; PHOSPHOLIPASE D; REACTIVE NITROGEN SPECIES;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CELL CYCLE PROGRESSION; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CROHN DISEASE; ENTERITIS; HUMAN; INTESTINE MUCOSA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; ULCERATIVE COLITIS; WNT SIGNALING PATHWAY; ANTIBACTERIAL ACTIVITY; CARCINOGENESIS; ENZYME INHIBITION; INFLAMMATORY BOWEL DISEASE; META ANALYSIS (TOPIC); NONHUMAN; RISK FACTOR; SYSTEMATIC REVIEW (TOPIC);

CHEMOPREVENTION; COLORECTAL NEOPLASMS; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; RISK FACTORS;

EID: 84884237159     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000353806     Document Type: Article

References (46)

1. Crohn BB, Rosenberg H: The sigmoidoscopic picture of chronic ulcerative colitis (non-specific). Am J Med Sci 1925; 170: 220-228.
2. Warren S, Sommers SC: Cicatrizing enteritis (regional ileitis) as a pathologic entity. Am J Pathol 1948; 24: 475-501.
3. Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-535.
4. Jess T, Rungoe C, Peyrin-Biroulet L: Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012; 10: 639-645.
5. Canavan C, Abrams KR, Mayberry J: Metaanalysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006; 23: 1097-1104.
6. Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI: Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005; 100: 2724-2729.
7. Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M: Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-381 e1, quiz e13-e14.
8. Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F: Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012; 143: 382-389.
9. Itzkowitz SH, Yio X: Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287:G7-G17.
10. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et al: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-459.
11. Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al: Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007; 133: 1099-1105, quiz 340-341.
12. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000; 95: 3452-3457.
13. Miyoshi J, Yajima T, Shimamura K, Matsuoka K, Okamoto S, Higuchi H, et al: 5-Aminosalicylic acid mediates expression of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase to suppress colorectal tumorigenesis. Anticancer Res 2012; 32: 1193-1202.
14. Baan B, Dihal AA, Hoff E, Bos CL, Voorneveld PW, Koelink PJ, et al: 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer. Gut 2012; 61: 1708-1715.
15. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al: Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004; 53: 1813-1816.
16. Romkens TE, Kampschreur MT, Drenth JP, van Oijen MG, de Jong DJ: High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials. Inflamm Bowel Dis 2012; 18: 2190-2198.
17. Lyakhovich A, Gasche C: Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 2010; 31: 202-209.
18. Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C: 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007; 132: 221-235.
19. Munding J, Ziebarth W, Pox CP, Ladigan S, Reiser M, Huppe D, et al: The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the beta-catenin signaling pathway. Carcinogenesis 2012; 33: 637-643.
20. Sun L, Wang X, Yao H, Li W, Son YO, Luo J, et al: Reactive oxygen species mediate Cr(VI)-induced S phase arrest through p53 in human colon cancer cells. J Environ Pathol Toxicol Oncol 2012; 31: 95-107.
21. Campregher C, Luciani MG, Biesenbach P, Evstatiev R, Lyakhovich A, Gasche C: The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity. Inflamm Bowel Dis 2010; 16: 576-582.
22. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H: Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005; 43: 3380-3389.
23. Subramanian S, Rhodes JM, Hart CA, Tam B, Roberts CL, Smith SL, et al: Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine. Inflamm Bowel Dis 2008; 14: 162-175.
24. Pinczowski D, Ekbom A, Baron J, Yuen J, Adami HO: Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994; 107: 117-120.
25. Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF: Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-1183.
26. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J: Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-153.
27. Bernstein CN, Blanchard JF, Metge C, Yogendran M: Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003; 98: 2784-2788.
28. Velayos FS, Terdiman JP, Walsh JM: Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 1345-1353.
29. Nguyen GC, Gulamhusein A, Bernstein CN: 5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol 2012; 107: 1298-1304, quiz 1297, 1305.
30. Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, et al: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis 2013; 7: 1-33.
31. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al: Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-1038.
32. Carrat F SP, Bouvier AM, et al: Aminosalicylates, thiopurines and the risk of colorectal cancer in inflammatory bowel diseases: a case-control study nested in the CESAME cohort. Gastroenterology 2010; 138:S-47.
33. van Schaik FD, van Oijen MG, Smeets HM, van der Heijden GJ, Siersema PD, Oldenburg B: Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut 2012; 61: 235-240.
34. Lutgens MW, Siersema PD, Vleggaar FP, et al: Different risk factors for colitis associated colorectal cancer in ulcerative colitis and Crohn's disease. Gastroenterology 2011; 140:S-351.
35. Baars JE, Looman CW, Steyerberg EW, Beukers R, Tan AC, Weusten BL, et al: The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2011; 106: 319-328.
36. Tang J, Sharif O, Pai C, Silverman AL: Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci 2010; 55: 1696-1703.
37. Ullman T, Croog V, Harpaz N, Hossain S, Kornbluth A, Bodian C, et al: Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol 2008; 6: 1225-1230, quiz 177.
38. Terdiman JP, Steinbuch M, Blumentals WA, Ullman TA, Rubin DT: 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 367-371.
39. Jess T, Loftus EV Jr, Velayos FS, Winther KV, Tremaine WJ, Zinsmeister AR, et al: Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007; 102: 829-836.
40. Rubin DT, LoSavio A, Yadron N, Huo D, Hanauer SB: Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 1346-1350.
41. Siegel CA, Sands BE: Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis 2006; 12: 491-496.
42. van Staa TP, Card T, Logan RF, Leufkens HG: 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 1573-1578.
43. Lindberg BU, Broome U, Persson B: Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001; 44: 77-85.
44. Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A: The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997; 112: 29-32.
45. Dignass A, Lindsay JO, Sturm A, Windsor A, Colombel JF, Allez M, et al: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. 2. Current management. J Crohns Colitis 2012; 6: 991-1030.
46. Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, et al: Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006; 130: 1941-1949.